General Information of This Drug (ID: DMN9RPO)

Drug Name
Nafcillin   DMN9RPO
Synonyms
Nafcilina; Nafcilline; Nafcillinum; Nallpen; Naphcillin; Naphthamidopenicillin; Unipen; NAFCILLIN SODIUM; Nafcillin sodium for injection; Nallpen In Plastic Container; Nafcilin-1; Nafcilina [INN-Spanish]; Nafcillin & VRC3375; Nafcillin (INN); Nafcillin [INN:BAN]; Nafcilline [INN-French]; Nafcillinum [INN-Latin]; Nafcillin, Monosodium Salt, Anhydrous; (2-Ethoxy-1-naphthyl)penicillin; (2-ethoxy-1-naphthalenyl)penicillin; (2S,5R,6R)-6-({[2-(ethyloxy)naphthalen-1-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-ethoxy-1-naphthamido)penicillanic acid; 6-[(2-Ethoxy-naphthalene-1-carbonyl)-amino]-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion; 6beta-(2-ethoxynaphthalene-1-carboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Staphylococcus aureus infection DISK6PTH N.A. Approved [1]
Staphylococcal pneumonia DIS28ZSZ N.A. Approved [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Staphylococcus infection DISY8WGS 1B5Y Discontinued in Phase 3 [2]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Arthritis DIST1YEL FA20 Discontinued in Phase 2 [3]
------------------------------------------------------------------------------------

References

1 Nafcillin FDA Label
2 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
3 Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer